Medicine
Oxymorphone 20 mg extended-release tablet
Oxymorphone 20 mg extended-release tablet is a generic prescription medicine for oral use, made by 2 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20° to 25°C (68° to 77°F). Store Oxymorphone Hydrochloride…
Key facts
- Active ingredient (INN)
- Oxymorphone
- Brand
- Sold under the generic name
- Strength
- 20 mg
- Dosage form
- Extended-release tablet
- Route
- Oral
- Packs
- 100 tablets, 1000 tablets, 30 tablets and 5 more
- Manufacturers
- Amneal PharmaceuticalsAmneal Pharmaceuticals of New York
- Origin register
- US FDA, United States
- Storage
- Store at 20° to 25°C (68° to 77°F). Store Oxymorphone Hydrochloride Extended-Release Tablets securely and dispose of properly.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Schedule CII
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 2 January 2013
- Identifiers
- RxCUI 977874, 977894, 977902 +4DailyMed set ID 557e9610-62d7-42bf-90c1-44215bd8c1f8, 3f4e703a-e398-42fd-8759-e398c79955f1NDC 0115-1233, 64896-699Application ANDA079087
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Packs from every labeler of this generic presentation.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 100 tablet, film coated, extended release in 1 bottle | 64896-699-01 | Amneal Pharmaceuticals | 2 January 2013 |
| 1000 tablet, film coated, extended release in 1 bottle | 64896-699-03 | Amneal Pharmaceuticals | 2 January 2013 |
| 30 tablet, film coated, extended release in 1 bottle | 64896-699-08 | Amneal Pharmaceuticals | 2 January 2013 |
| 60 tablet, film coated, extended release in 1 bottle | 64896-699-13 | Amneal Pharmaceuticals | 2 January 2013 |
| 100 tablet, film coated, extended release in 1 bottle | 0115-1233-01 | Amneal Pharmaceuticals of New York | 2 January 2013 |
| 1000 tablet, film coated, extended release in 1 bottle | 0115-1233-03 | Amneal Pharmaceuticals of New York | 2 January 2013 |
| 30 tablet, film coated, extended release in 1 bottle | 0115-1233-08 | Amneal Pharmaceuticals of New York | 2 January 2013 |
| 60 tablet, film coated, extended release in 1 bottle | 0115-1233-13 | Amneal Pharmaceuticals of New York | 2 January 2013 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 2 April 1959 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Oxymorphone
Clinical summary
Oxymorphone is an opioid agonist indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. It is available as extended-release tablets and tablets for oral use. MedsAcross supplies Oxymorphone for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about OxymorphoneFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Oxymorphone Hydrochloride prescribing information (Aurolife Pharma) · U.S. National Library of Medicine, DailyMed
Need Oxymorphone 20 mg extended-release tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.